A study of platelet functions with a new analyzer using high shear stress (PFA 100(TM)) in patients undergoing coronary artery bypass graft

Thrombosis and Haemostasis

Volumn 84, Issue 5, 2000, Pages 794-799

  Lasne, D ^a   Fiemeyer, A ^a   Chatellier, G ^a   Chammas, C ^a   Baron, J F ^a   Aiach, M ^a  

^a HÔPITAL BROUSSAIS   (France)

Author keywords

Cardiopulmonary bypass; In vitro bleeding time; PFA100(TM); Platelet function

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; COLLAGEN; HEPARIN; PROTAMINE; TICLOPIDINE; VON WILLEBRAND FACTOR;

ADULT; AGED; ANALYZER; ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; BLEEDING; BLEEDING TIME; BLOOD ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; FEMALE; HEMATOCRIT; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SHEAR STRESS; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION;

EID: 0033678065     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614118     Document Type: Article

References (27)

1. The standardization of certain factors in cutaneous 'venostasis' bleeding time technique
2. The bleeding time does not predict surgical bleeding
3. Bleeding time and bleeding: An analysis of the relationship of the bleeding time test with parameters of surgical bleeding
4. Description of an in vitro platelet function analyzer-PFA100
5. Preliminary data from a field trial of the PFA-100 system
6. Screening for von Willebrand disease with a new analyzer using high shear stress: A study of 60 cases
7. The platelet function analyzer (PFA-100): A novel in-vitro system for evaluation of primary haemostasis in children
8. Evaluation of the PFA100® system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease
9. Proposal of an algorithm to help the choice of the best transfusion strategy
10. The effect of ABO blood group on the diagnosis of von Willebrand disease
11. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: Acquired transient platelet dysfunction associated with selective alpha granule release
12. Decreased platelet number and function and increased fibrinolysis contribute to post-operative bleeding in cardiopulmonary bypass patients
13. Significant reduction in the binding of a monoclonal antibody (LYP18) directed against the IIb/IIIa glycoprotein complex to platelets of patients having undergone extracorporeal circulation
14. Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting
15. Veteran administration group. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy
16. Evaluation of platelet function by PFA-100
17. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood
18. PFA-100 system: A new method for assessment of platelet dysfunction
19. Are in-vitro platelet function tests useful in predicting blood loss following open heart surgery?
20. Autopsy findings in three patients with von Willebrand disease type IIB and type III: Presence of atherosclerotic lesions without occlusive arterial thrombi
21. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): Influence of hematocrit elevation
22. Disappearance of glycoprotein Ib from the platelet surface in pericardial blood during cardiopulmonary bypass
23. The effects of aspirin and hypothermia on platelet function in vivo
24. Shear-mediated platelet dysfunction during cardiac surgery: Mechanism and clinical implications
25. The effects of cardiopulmonary bypass on systemic and coronary levels of von Willebrand factors
26. The role of von Willebrand factor in haemostasis and blood loss during and after cardiopulmonary bypass
27. HES 200/0.5 is not HES 200/0.5. Influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl Starch (HES) on hemorheology, coagulation and elimination kinetics